Cancer Genetics to Report First Quarter Financial Results on Tuesday, May 12

RUTHERFORD, N.J., May 5, 2015 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics, announced today that it will report financial results for the first quarter ended March 31, 2015 before the market opens on Tuesday, May 12, 2015. The company will hold a live investor conference call and webcast at 8:30am Eastern on the same day.

Conference Call & Webcast

Tuesday, May 12, 2015 at 8:30 a.m. Eastern Time/5:30 a.m. Pacific Time

Domestic: 877-407-4018
International: 201-689-8471
Conference ID: 13606598
Replays – Available through May 26, 2015
Domestic: 877-870-5176
International: 858-384-5517
Conference ID: 13606598

Note: Please check that your computer operating system supports the call by joining a few minutes before 8:30am.

About Cancer Genetics

Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference labs are focused entirely on maintaining clinical excellence and are both CLIA certified and CAP accredited and have licensure from several states including New York State. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute.

For more information, please visit or follow us:


Twitter: @Cancer_Genetics


CONTACT: Investor Relations Hans Vitzthum LifeSci Advisors, LLC 212-915-2568 Media Relations Marie Patrone-Michellod Cancer Genetics, Inc. 201-528-9182

Source:Cancer Genetics, Inc.